FTC/RPV/TAF Placebo

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1 Infection

Phase 3

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

CompletedNCT02345252

Gilead SciencesHIV-1 Infection

Start: 2015-01-26End: 2019-01-09Updated: 2020-01-02

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

CompletedNCT02345226

Gilead SciencesHIV-1 Infection

Start: 2015-01-26End: 2019-01-02Updated: 2020-01-02

Related Papers

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

2017-03-0237 citations